#United States #Salt Lake City #Lipocine #LPCN #Brexanolone

Lipocine Inc. to Present at H.C. Wainwright 27th Annual Conference

Lipocine Inc. (NASDAQ: LPCN), a pioneering biopharmaceutical company, is set to make waves at the upcoming H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025. This prestigious event will be held both in-person and virtually, enabling a broad audience of investors and industry stakeholders to engage with the company’s management and gain insights into its groundbreaking drug development programs.

Event Details

The presentation will commence at 7:00 AM EDT on September 5, 2025, allowing time for investors to interact with Lipocine’s management team to discuss their innovative technology platform and the unique products they are currently developing. Registrations for the conference can be made through the official H.C. Wainwright website, and those interested in one-on-one meetings with Lipocine representatives should reach out to their respective H.C. Wainwright contacts.

About Lipocine Inc.

Founded with the vision of addressing unmet medical needs through innovative solutions, Lipocine Inc. focuses on developing products that facilitate effective oral delivery. With a robust portfolio of drug candidates, Lipocine aims to change the landscape of biopharmaceuticals. Their pipeline includes several noteworthy candidates targeting major medical conditions:

• - LPCN 1154: An oral formulation of brexanolone aimed at treating postpartum depression.
• - LPCN 2101: Targeting epilepsy, this candidate represents another crucial area of focus for the company.
• - LPCN 2203: Developed for essential tremor management, this candidate showcases Lipocine's commitment to patient-centric solutions.
• - LPCN 2401: This anabolic androgen receptor agonist is intended to improve body composition in obesity management and has potential applications alongside incretin mimetics.
• - LPCN 1148: A novel androgen receptor agonist prodrug focusing on symptoms associated with liver cirrhosis, showcasing Lipocine's innovative approach to medication.

Lipocine is also seeking partnerships for LPCN 1107, which targets preterm birth prevention, as well as continuing to develop its candidates for conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and decompensated cirrhosis. In addition, TLANDO, a novel oral prodrug of testosterone, has received FDA approval for treating adult male hypogonadism, further solidifying Lipocine's place in the biopharmaceutical landscape.

Impact of the Conference

The H.C. Wainwright Global Investment Conference represents an excellent opportunity for Lipocine to highlight its innovative work and strategic direction to a relevant audience. This platform will not only enhance investor understanding of Lipocine's objectives but also promote collaboration opportunities that can lead to further advancements in biopharmaceuticals.

With a commitment to transforming patient care through effective solutions, Lipocine is poised to make significant contributions to the healthcare industry. The upcoming conference will be a crucial step in facilitating discussions around their promising product pipeline and the future of the company. For more detailed information about their projects, visit www.lipocine.com.